Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market to Observe Stupendous Growth During the Forecast Period (2022-2032) - DelveInsight | Key Companies - Argenx, GeNeuro, Pfizer, Cellenkos, HarbourBioMed, Takeda, Sanofi, Biogen Idec, Shire

As per DelveInsight, the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market is anticipated to grow immensely in the coming years owing to the rising prevalent population and awareness of CIDP patients in the 7MM. Along with these, the development of advanced technologies will also give robust growth to the market.

The CIDP treatment landscape continues to evolve, and several companies are furiously working toward developing new treatments that could potentially cure and change the treatment landscape of CIDP. Companies are focused on developing FcRN-targeting therapies for the treatment of CIDP; this shall create a positive impact on the market size of the disease in the coming years. Currently, some of the key companies, like Argenx, Sanofi, Takeda, and others, are working in the therapeutics market.

DelveInsight's "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Chronic Inflammatory Demyelinating Polyneuropathy Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Chronic Inflammatory Demyelinating Polyneuropathy market report covers emerging drugs, treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): An Overview
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms, mainly caused by damage to the myelin sheath of the peripheral nerves. It is an acquired peripheral neuropathy due to an autoimmune attack of peripheral nerve myelin. Myelin is the main target of the condition, in which patients present with weakness, numbness, and sensory ataxia.

The main signs of CIDP are symmetrical weakness in both hands, feet, hip, and shoulder muscles that slowly progresses (over at least 2 months) (both proximal and distal muscles). If nerve injury is the cause of this pattern of weakness, CIDP is most likely to be the reason. Nerve signals deteriorate, resulting in abnormal or lost sensation and/or impaired motor function.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Key Facts
- The total prevalent population of CIDP in the 7MM was ~45,200 in 2019 and is expected to rise in 2032 during the study period [2019-2032].
- Estimates show that the United States accounts for the highest cases (approximately 65%) of total CIDP cases, as compared to EU5 and Japan.
- Among the European 5 countries, France had the highest prevalent population of CIDP with ~3,800 cases, followed by Germany and the UK. On the other hand, Spain had the lowest prevalent population of CIDP, with 1,900 cases in 2019.
- According to Lehmann et al. (2019), the reported prevalence of CIDP is 2.84 per 100,000 people. In this study, male patients outnumbered females by 2:1, and CIDP was more prevalent in advanced age.
- According to Broers et al. (2019), the crude prevalence is estimated at 2.81 cases per 100,000 persons. Additionally, males are overrepresented in comparison to females.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Chronic Inflammatory Demyelinating Polyneuropathy market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the Chronic Inflammatory Demyelinating Polyneuropathy market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Discover How Chronic Inflammatory Demyelinating Polyneuropathy Market will Grow by 2032:
https://www.delveinsight.com/report-store/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Epidemiology
The epidemiology section covers detailed insights into the historical and current Chronic Inflammatory Demyelinating Polyneuropathy patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032.

Get Key Insights Into the Evolving Chronic Inflammatory Demyelinating Polyneuropathy Epidemiology Trends:
https://www.delveinsight.com/report-store/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

The Report Covers the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Epidemiology Segmented by -
- Total Prevalent Pool of CIDP (2019-2032)
- Gender-specific Prevalent Pool of CIDP (2019-2032)
- Age-specific Prevalent Pool of CIDP (2019-2032)
- Clinical Subtype-based (Typical/Atypical) Diagnosed Prevalent Pool of CIDP (2019-2032)

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Inflammatory Demyelinating Polyneuropathy market or expected to be launched during the study period. The analysis covers the Chronic Inflammatory Demyelinating Polyneuropathy market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Chronic Inflammatory Demyelinating Polyneuropathy Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities:
https://www.delveinsight.com/report-store/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Therapeutics Assessment
The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Therapeutics market dynamics is anticipated to change in the coming years owing to the expected launch of Targeted therapies. Several major pharma and biotech giants are developing therapies for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Currently, Argenx is leading the therapeutics market with its Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) drug candidates in the most advanced stage of clinical development.

The Leading Companies in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Therapeutics Market Include:
- Argenx
- Roche
- MedDay Pharmaceuticals
- Momenta Pharmaceuticals
- UCB
- GeNeuro
- Takeda
And Many Others

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Therapies Covered in the Report Include:
- Efgartigimod: Argenx
- Temelimab: GeNeuro
- PF-06755347: Pfizer
- CK0803: Cellenkos
- Batoclimab: HarbourBioMed
- HYQVIA: Takeda
- SAR445088: Sanofi
- Rituximab: Biogen Idec
- Shire/Takeda: HyQvia
And Many More

Learn More About the Emerging Therapies & Key Companies in the Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Market:
https://www.delveinsight.com/sample-request/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Chronic Inflammatory Demyelinating Polyneuropathy Competitive Intelligence Analysis
4. Chronic Inflammatory Demyelinating Polyneuropathy Market Overview at a Glance
5. Chronic Inflammatory Demyelinating Polyneuropathy Background and Overview
6. Chronic Inflammatory Demyelinating Polyneuropathy Patient Journey
7. Chronic Inflammatory Demyelinating Polyneuropathy Epidemiology and Patient Population
8. Chronic Inflammatory Demyelinating Polyneuropathy Treatment Algorithm, Current Treatment, and Medical Practices
9. Chronic Inflammatory Demyelinating Polyneuropathy Unmet Needs
10. Key Endpoints of Chronic Inflammatory Demyelinating Polyneuropathy Treatment
11. Chronic Inflammatory Demyelinating Polyneuropathy Marketed Products
12. Chronic Inflammatory Demyelinating Polyneuropathy Emerging Therapies
13. Chronic Inflammatory Demyelinating Polyneuropathy Seven Major Market Analysis
14. Attribute Analysis
15. Chronic Inflammatory Demyelinating Polyneuropathy Market Outlook (7 major markets)
16. Chronic Inflammatory Demyelinating Polyneuropathy Access and Reimbursement Overview
17. KOL Views on the Chronic Inflammatory Demyelinating Polyneuropathy Market.
18. Chronic Inflammatory Demyelinating Polyneuropathy Market Drivers
19. Chronic Inflammatory Demyelinating Polyneuropathy Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings:
https://www.delveinsight.com/sample-request/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com
Request for Sample Copy of the Report at:
https://www.delveinsight.com/sample-request/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

elveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.